223718-30-7

Basic information

• Product Name: 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one
• Synonyms: 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one
• CAS NO: 223718-30-7
• Molecular Weight: 325.321
• Mol File: 223718-30-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one(223718-30-7)
• EPA Substance Registry System: 3-(benzyloxycarbonyl)amino-7-hydroxy-8-methyl-2H-1-benzopyran-2-one(223718-30-7)

Safety Data

• Hazardous Substances Data: 223718-30-7(Hazardous Substances Data)

Upstream product

• 329358-96-5 methyl-2-(benzyloxy carbonyl)amino-3-dimethylaminopropenoate 
• 608-25-3 2-methylbenzene-1,3-diol 
• 1083312-76-8 2-iodo-1,3-bis(methoxymethoxy)benzene 
• 1083312-74-6 5-methoxy-1,3-bis(methoxymethoxy)-2-methylphenol 
• 15805-73-9 vinyl carbamate 
• 57234-29-4 1,3-bis(methoxymethyl)resorcinol 
• 108-46-3 recorcinol 
• 100-39-0 benzyl bromide 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 1212-53-9 methyl N-benzyloxycarbonylglycinate 
• 219739-90-9 Methyl (Z)-2-<(benzyloxycarbonyl)amino>-3-dimethylaminopropenoate 

Downstream Products

• 915118-11-5 benzyl-7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl carbamate 
• 3769-40-2 2-(phenylmethyl)-1,3-dihydroxybenzene 
• 1990-85-8 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid 
• 1239437-77-4 4-(7-(Methoxymethoxy)-8-methyl-2-oxo-2H-chromen-3-ylcarbamoyl)-2-(3-methylbut-2-enyl)phenyl acetate 

Relevant articles and documents

Exploiting polarity and chirality to probe the Hsp90 C-terminus

Inhibition of the Hsp90 C-terminus is an attractive therapeutic approach for the treatment of cancer. Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically complex noviose sugar that has limited the generation of structure-

Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines

(Chemical Equation Presented) Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degradation of Hsp90-dependent client proteins at ～700 μM. As a result of these studies, several analogues of the coumarin family of antibiotics have been reported and shown to exhibit increased Hsp90 inhibitory activity; however, the monomeric species lacked the ability to manifest anti-proliferative activity against cancer cell lines at concentrations tested. In an effort to develop more efficacious compounds that produce growth inhibitory activity against cancer cell lines, structure - activity relationships were investigated surrounding the prenylated benzamide side chain of the natural product. Results obtained from these studies have produced the first novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.

Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery

(Chemical Equation Presented) The coumarin antibiotics are not only potent inhibitors of DNA gyrase but also represent the most effective C-terminal inhibitors of 90 kDa heat shock proteins (Hsp90) reported thus far. In contrast to the N-terminal ATP-binding site, little is known about the Hsp90 C-terminus. In addition, very limited structure-activity relationships exist between this class of natural products and Hsp90. In this letter, the syntheses of dimeric coumarin analogues are presented along with their inhibitory values in breast cancer cell lines.